Core Viewpoint - The increasing popularity of A-shares has led many public fund managers to open real-time trading accounts on online platforms to showcase their performance [1][2]. Group 1: Fund Managers Opening Real Accounts - Numerous public fund managers, including those from Guojin Fund and Guotai Fund, have opened real accounts on platforms like Tiantian Fund and Ant Wealth [2][10]. - The total amount of these real accounts is generally high, with some exceeding 4 million yuan, such as Guojin Fund's Yao Jiahong, whose account reached 4.1394 million yuan [11]. Group 2: Performance and Investment Choices - Some fund managers have reported holding profits exceeding 1 million yuan, indicating positive returns [3][13]. - Fund managers predominantly invest in their own products or those from their fund companies, with no evidence of investing in products from other companies [8][9]. Group 3: Comparison with Retail Investors - Despite the reported profits, fund managers' returns often lag behind those of ordinary investors, with the top retail investors achieving monthly returns between 30.41% and 39.39% [16][17]. - Over the past year, no fund manager has made it to the top performance rankings, which raises questions about their short-term investment capabilities compared to retail investors [18][19]. Group 4: Implications and Industry Perspectives - The practice of fund managers opening real accounts may enhance trust and transparency with investors, especially for smaller firms or emerging managers [22][23]. - However, there are concerns that these accounts primarily serve as a marketing tool for their own products rather than providing genuine investment insights [12][21][26].

"晒实盘"正在成为基金经理之间的"新比拼"。 有人大手笔投资盈利110万元；有人用十余万元定投斩获120%收益；还有人多元配置指基，持仓页面"满屏皆 红"。热闹的表象之下，是行业透明度提升、投资者专业化需求升级与营销模式转型的共振。 基金经理实盘收益颇丰 随着市场上行，多位基金经理的基金实盘战绩可观，"豪掷百万"的也不少： | 童类公自 | 基金经理 | 累计收益 | 实营命额 | 平台 | | --- | --- | --- | --- | --- | | | | (万元) | (万元) | | | 国等意等 | 姚加红 | 113.36 | 413.94 | 蚂蚁财富 | | 国等意金 | 马芳 | 62.78 | 198.3 | 蚂蚁财富 | | 国泰县金 | 梁杏 | 33.68 | 137.99 | 蚂蚁财富 | | 蒸元基金 | 刘俊文 | 16.44 | 130.19 | 天天县金 | | 永赢基金 | 张璐 | 16.24 | 52.89 | 蚂蚁财富 | | 永赢县金 | 任桀 | 15.74 | 29.54 | 天天基金 | | 上银套金 | 卢扬 | 7.93 | 54.85 | 蚂蚁财 ...

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Innovative Drug Industry Index, which rose by 2.51% to 1955.39 points, with a trading volume of 33.441 billion yuan [1] - The index has shown significant growth, increasing by 6.55% over the past month, 12.29% over the past three months, and 22.60% year-to-date [1] - The index is composed of up to 50 representative securities from the mainland and Hong Kong markets, focusing on companies involved in innovative drug research and production, reflecting the overall performance of the innovative drug industry [1] Group 2 - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year [1] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [1] - The index will be modified if a sample company is delisted or if there are significant corporate changes such as mergers or acquisitions [1] Group 3 - Public funds tracking the SHS Innovative Drug Index include various ETFs and fund products from companies like Guotai, Xizang Dongcai, and Huatai Bairui [2]